Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2025)

Historic Accumulated Depreciation for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $16.8 million.

  • SAB Biotherapeutics' Accumulated Depreciation rose 2145.64% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 2145.64%. This contributed to the annual value of $14.6 million for FY2024, which is 4703.52% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Accumulated Depreciation of $16.8 million as of Q3 2025, which was up 2145.64% from $16.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Accumulated Depreciation ranged from a high of $16.8 million in Q3 2025 and a low of $3.2 million during Q4 2021
  • For the 5-year period, SAB Biotherapeutics' Accumulated Depreciation averaged around $10.2 million, with its median value being $10.9 million (2023).
  • In the last 5 years, SAB Biotherapeutics' Accumulated Depreciation surged by 9498.42% in 2022 and then surged by 2145.64% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Accumulated Depreciation stood at $3.2 million in 2021, then surged by 94.98% to $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then rose by 15.42% to $16.8 million in 2025.
  • Its Accumulated Depreciation stands at $16.8 million for Q3 2025, versus $16.1 million for Q2 2025 and $15.3 million for Q1 2025.